company background image
SNT logo

Syntara ASX:SNT Stock Report

Last Price

AU$0.02

Market Cap

AU$23.9m

7D

0%

1Y

-54.5%

Updated

27 Mar, 2024

Data

Company Financials +

SNT Stock Overview

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers.

SNT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Syntara Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syntara
Historical stock prices
Current Share PriceAU$0.02
52 Week HighAU$0.063
52 Week LowAU$0.016
Beta0.56
1 Month Change-13.04%
3 Month Change-9.09%
1 Year Change-54.55%
3 Year Change-75.31%
5 Year Change-92.31%
Change since IPO-95.56%

Recent News & Updates

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14
Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Recent updates

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14
Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Oct 27
Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Mar 01
Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04
We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Shareholder Returns

SNTAU PharmaceuticalsAU Market
7D0%-0.06%1.0%
1Y-54.5%39.3%11.3%

Return vs Industry: SNT underperformed the Australian Pharmaceuticals industry which returned 39.3% over the past year.

Return vs Market: SNT underperformed the Australian Market which returned 11.3% over the past year.

Price Volatility

Is SNT's price volatile compared to industry and market?
SNT volatility
SNT Average Weekly Movement13.3%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.2%
10% least volatile stocks in AU Market3.2%

Stable Share Price: SNT's share price has been volatile over the past 3 months.

Volatility Over Time: SNT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
199827Gary Phillipshttps://www.syntaratx.com.au

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023.

Syntara Limited Fundamentals Summary

How do Syntara's earnings and revenue compare to its market cap?
SNT fundamental statistics
Market capAU$23.88m
Earnings (TTM)-AU$10.69m
Revenue (TTM)AU$19.18m

1.2x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNT income statement (TTM)
RevenueAU$19.18m
Cost of RevenueAU$11.31m
Gross ProfitAU$7.87m
Other ExpensesAU$18.56m
Earnings-AU$10.69m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.009
Gross Margin41.03%
Net Profit Margin-55.77%
Debt/Equity Ratio0%

How did SNT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.